Noile-Immune Biotech Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	4,118	4,670	5,555	4,520	4,140	2,548
Cash & Short-Term Investments	4,118	4,670	5,555	4,520	4,140	2,548
Cash Growth	-12.68%	-15.93%	22.90%	9.18%	62.48%	-
Accounts Receivable	-	-	-	-	-	3
Other Receivables	21	62	66	-	53	48
Receivables	21	62	66	-	53	51
Inventory	6	8	20	3	4	10
Prepaid Expenses	16	29	38	27	25	21
Other Current Assets	6	6	38	34	3	29
Total Current Assets	4,167	4,775	5,717	4,584	4,225	2,659
Long-Term Investments	26	24	61	56	45	15
Other Long-Term Assets	1	1	-	1	1	-
Total Assets	4,194	4,800	5,778	4,641	4,271	2,674
Accounts Payable	1	-	1	-	-	-
Accrued Expenses	39	27	29	45	20	17
Current Income Taxes Payable	24	32	48	235	51	13
Other Current Liabilities	4	10	8	55	9	40
Total Current Liabilities	68	69	86	335	80	70
Other Long-Term Liabilities	7	7	6	7	6	6
Total Liabilities	75	76	92	342	86	76
Common Stock	4,047	4,047	4,045	2,787	2,537	1,346
Additional Paid-In Capital	4,025	4,025	4,023	2,765	2,515	1,324
Retained Earnings	-3,958	-3,353	-2,389	-1,259	-872	-77
Comprehensive Income & Other	5	5	7	6	5	5
Shareholders' Equity	4,119	4,724	5,686	4,299	4,185	2,598
Total Liabilities & Equity	4,194	4,800	5,778	4,641	4,271	2,674
Net Cash (Debt)	4,118	4,670	5,555	4,520	4,140	2,548
Net Cash Growth	-12.68%	-15.93%	22.90%	9.18%	62.48%	-
Net Cash Per Share	95.10	107.86	133.96	115.40	108.06	71.75
Filing Date Shares Outstanding	43.3	43.3	43.3	39.58	38.31	35.51
Total Common Shares Outstanding	43.3	43.3	43.3	39.58	38.31	35.51
Working Capital	4,099	4,706	5,631	4,249	4,145	2,589
Book Value Per Share	95.12	109.09	131.33	108.60	109.23	73.16
Tangible Book Value	4,119	4,724	5,686	4,299	4,185	2,598
Tangible Book Value Per Share	95.12	109.09	131.33	108.60	109.23	73.16

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.